DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Corticorelin
Corticorelin
The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands
List of Approved Ndas for Biological Products That Were Deemed to Be Blas on March 23, 2020
Corticorelin Acetate, a Synthetic Corticotropin-Releasing Factor with Preclinical Antitumor Activity, Alone and with Bevacizumab, Against Human Brain Tumor Models
BCBSVT Specialty Drug List Effective 2021.07.01.Xlsx
Preferred Drug List (Formulary)
September 2017 ~ Resource #330909
Michigan Department of Health and Human Services Practitioner and Medical Clinic Fee Schedule Revised: 04/06/2016 January - 2016
Pharmaceutical Appendix to the Harmonized Tariff Schedule
CDER List of Licensed Biological Products With
Michigan Department of Health and Human Services Practitioner and Medical Clinic Fee Schedule July - 2015 Revised: 09/30/2015 9:58:24 AM
Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
Injectable Medication Hcpcs/Dofr Crosswalk
Stembook 2018.Pdf
INN Working Document 05.179 Update December 2010
Corticotropin(BAN, Rinn) ⊗
(INN) for Biological and Biotechnological Substances
(12) Patent Application Publication (10) Pub. No.: US 2010/013.6614 A1 Luo Et Al
Category Catalog CAS Product Name Description Alias/Synonym Application M.F/Formula M.W/Mr
Top View
Improved Response of Growth Hormone to Growth Hormone
Division of Vital Statistics, Mortality Data Table Page 1 of 147
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
List of Off-Patent, Off-Exclusivity Drugs Without an Approved Generic
International Nonproprietary Names for Biological and Biotechnological Substances: a Review17
Endocrine Dynamic Function Test Protocols for Use in Neonates and Children Contents
Customs Tariff - Schedule
Preliminary List of Approved Ndas for Biological Products That Will Be Deemed to Be Blas on March 23, 2020 (Current As of December 31, 2019)
(12) United States Patent (Io) Patent No.: US 9,526,824 B2 Ferrari Et Al
Anti-Pituitary Antibodies and Susceptible Human Leukocyte
U.S. Department of Labor, Office of Workers
HA Drug Formulary External List V12 2 161008 (Dated 161006).Xlsx
HOSPITAL AUTHORITY DRUG FORMULARY (V17.1 - W.E.F
Endocrine Test Protocols
State and Specialty Pharmacy Drug Reimbursement Rates
International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
Wo 2007/044693 A2
Advances in Therapeutic Peptides Targeting G Protein-Coupled Receptors
Ohio Medicaid ESRD Contract 09-03-2021
(2) Patent Application Publication (10) Pub. No.: US 2011/0288011 A1 Castaigne Et Al
Harmonized Tariff Schedule of the United States (2006) (Rev
SHCA Prior Authorization Grid
Drugs Formulary
AHFS Pharmacologic-Therapeutic Classification System
Gpcrs As Targets for Approved Drugs: How Many Targets and How Many Drugs?
Geisinger Wyoming Valley Hosptial MEDICATIONS PUBLISHED: January 1, 2019
2020 Table of Drugs
The Role of Counter-Ions in Peptides—An Overview
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Title 16. Crimes and Offenses Chapter 13
G Protein-Coupled Receptors As Targets for Approved Drugs: How Many Targets and How Many Drugs? S
Title List Patient Education Text Drug Information
WO 2010/063124 Al
Immune Checkpoint Inhibitor Combination Therapies Very
FOI 280 1617 Document 3
Geisinger Community Medical Center Medications Published: February 1, 2020
List of Covered Drugs
Of 7 Reference ID: 3814083 Secretory Episodes of ACTH Each Day
HCPCS/Drug Code List Version 11.9 Revised 4/8/19 List Will Be Updated
WO 2018/156617 A2 30 August 2018 (30.08.2018) W !P O PCT
2014 Table of Drugs
PRAC Agenda 08-11 June 2020
Internal Medicine Vol.55
Transmembrane Signal Transduction by Peptide Hormones Via Family B G Protein-Coupled Receptors
Obesity and Endocrine Management of the Patient with Duchenne Muscular Dystrophy David R